UNSPSC 51333514: Pridinol methanesulfonate

This classification denotes an antipsychotic agent with the molecular formula C20H25NO.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AQ4K0AJT6G, chemically known as 1,1-diphenyl-3-piperidinopropan-1-ol methanesulphonate, but more generally known as pridinol methanesulfonate, which bears US NIH Compound Identifier 165542. European Medicines Agency schedules pridinol methanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10037MIG.

Most nations, for tariff purposes, schedule pridinol methanesulfonate under HS 29333999. SMILES: CS(=O)(=O)O.C1CCC(CC1)C(CCN2CCCCC2)(C3CCCCC3)O.

UNSPSC 51333514 Pridinol methanesulfonate is a Commodity code that does not reflect the work actually being solicited under it in recent state and local procurement activity. The three most recent opportunities posted under this code — Seminole County's naloxone and drug deactivation system procurement, Texas HHS's Therapeutic Pharmacy Initiative direct-to-manufacturer RFI, and Minnesota MMCAP's generic multi-source pharmaceutical and OTC products RFP — address naloxone distribution, pharmacy benefit management infrastructure, and multi-state generic pharmaceutical supply respectively, none of which involve pridinol methanesulfonate specifically. The code shows a significant mismatch between its nominal scope and current purchasing intent.

Activity under this code spans state health and human services departments, county public health agencies, and multi-state cooperative purchasing alliances, with geographic spread across Florida, Texas, Minnesota, and Oregon in the recent record. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 drug deactivation systems annually with a response deadline of July 26, 2026. Texas HHS issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs. Minnesota MMCAP, administered through the Department of Administration's Office of State Procurement and including participating Oregon jurisdictions, posted RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, for multi-state supply of generic pharmaceuticals and OTC products through authorized wholesalers. The code itself appears to carry limited relevance to current state and local pharmaceutical procurement strategy; business development professionals should verify tagging accuracy before allocating pursuit resources.